What is the primary goal of this research?
The primary objective of this research was to evaluate the cost-effectiveness of icosapent ethyl compared to best supportive care in preventing major adverse cardiovascular events. This evaluation was conducted from the Catalonian healthcare perspective, focusing on patients with established cardiovascular disease and a recent acute coronary syndrome.
We adapted an existing partitioned survival model for icosapent ethyl, previously developed by FIECON, using Spanish cost and population data inputs. The key clinical data driving the model were drawn from a subpopulation of patients with recent acute coronary syndrome in the REDUCE-IT trial. This phase III randomised clinical trial evaluated the time to the occurrence of non-fatal myocardial infarction, non-fatal stroke, unstable angina, coronary revascularisation, or cardiovascular death in patients treated with either icosapent ethyl or a placebo.
We worked closely with a local cardiovascular expert in Catalonia to ensure the model used the most relevant and accurate inputs. This collaboration allowed us to tailor the model to the target population, ensuring its generalisability to the local healthcare setting.
One challenge we faced was the use of a mineral oil placebo in the control arm of the REDUCE-IT trial, which introduced some uncertainty regarding the true treatment effect of icosapent ethyl. To address this potential limitation, we applied a conservative negative adjustment to the treatment effect in the base case of our model. Despite this adjustment, the model demonstrated that icosapent ethyl remains a cost-effective treatment in Catalonia. Sensitivity analyses confirmed the robustness of our results, even when varying key input values.
Laurence is a Senior Associate at FIECON focused on delivering high-quality HEOR and Access solutions. With experience in cost-effectiveness and budget impact modelling, systematic literature reviews and value communication materials, Laurence has supported several successful HTA submissions for NICE and the SMC. His expertise spans a wide range of therapeutic areas, including oncology, cardiovascular disease and rare diseases.
To learn more about the poster, please visit: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4016/143694
Attending ISPOR Europe in Barcelona? Don’t miss the chance to meet the FIECON team at stand #1201. Let's discuss the research poster findings and explore how FIECON can elevate your market access and product launch as your commercial partner.
